Member Info for Bladderman

AVCT also great but yes already £230M.
All will go higher just to me GDR seems the most undervalued and by some distance as we all agree

Currently is 4x cheaper than NCYT (4x66=264)
Not for long one would imagine. In June we could very well be on par

And at 200p is still only £70 MCap which is £190M cheaper than NCYT

NCYT still valued at £266 which is great as at £66M
for GDR I'm seeing plenty of upside from here! Once the quiet period cools off and we head into close then we could easily bounce back to over £2

I think the predictions are because a lot of us are very relaxed about the future here. £65M just isn't fair value and over the next few weeks could be re-valued anywhere from £100-250M which is great for all holders. Some have gone rainbow chasing but ultimately this is now a micro cap company with an extremely-bright immediate future with many irons in the fire with anticpated positive news flow to back the rises.

HEMO is a vaccine venture. We have 10k per hour Cytiva backed test production coming on line so please don't compare

Short trading week too. People will want in before anticipated news lands. Surely a 50% up lift upon CE approval. At £2.50 Could become £3.75 which is only £130M

Don't start being pathetic Cold Spy. If you sold cool. But don't keep posting to suit your agenda please it's poor form

Distribution agreements.
The other assay test pipeline development.
Pre-order sales updates.
CE approval
All near term
Downstream FDA approval
All for £66M!

At 188p is £67M - peanuts for the mass testing assay that we're about to release to market!

Heading over a £100M MCap

At £75M is a joke....long long way to go

Lol

Yes Cold - I learnt that one recently.
FDA approved Cytiva backed NCYT. Surely they'll back GDR's Cytiva backed assay too. We passed Cytiva's 3 milestone test validation. £100M plus here we come

The CEO David Budd commented that ...
"we remain confident that this assay will make a significant contribution to the testing market."

They're going to supply a lot of tests to the market. Demand will become unprecedented for the foreseeable future

NCYT currently are producing 4M tests with a target of 8M tests. Puts things into perspective

I was being UBER conservative. If £6 a test then that is pretty much our MCap in one month (£55M).
In six months that's either £240M or £480M revenue pending on whether £3 or £6 a test. Cytiva has presence in 40 countries too. All about the MCap here as we know

Now the ambiguity has been removed by the website a potential of 8M at £3 a test could be £24M revenue a month here.

Fantastic Scart!! I emailed them last night too.

£2 this week incoming I reckon. Apparently, 180p the next target after 1.41p taken out.
ii 's will start kicking in with buying power above £50M MCap

Scalable manufacturing rate of 10k per hour ...

https://www.linkedin.com/posts/genedrive-plc_covid19-coronavirus-cytiva-activity-6657888370905141248-by_y

Going to be massive (£48M MCap is simply disconnected from the significance of this COVID test)